Syros Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
Other corporations in the scoring industry group for Syros Pharmaceuticals Inc are displayed. Comprehensive ESG analysis of Syros Pharmaceuticals Inc are reached by signing up for free. Scroll down to the bottom of this webpage for potential risks for Syros Pharmaceuticals Inc based on industry, geography and size.
Syros Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.3; made up of an environmental score of 6.0, social score of 8.0 and governance score of 8.0.
7.3
High ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
160 | YungShin Global Holding Corp | 7.5 | High |
160 | Zentiva SA | 7.5 | High |
191 | Syros Pharmaceuticals Inc | 7.3 | High |
191 | Cellectis SA | 7.3 | High |
191 | Aurinia Pharmaceuticals Inc | 7.3 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Syros Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Does Syros Pharmaceuticals Inc disclose current and historical energy intensity?
Does Syros Pharmaceuticals Inc report the average age of the workforce?
Does Syros Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Does Syros Pharmaceuticals Inc disclose its ethnicity pay gap?
Does Syros Pharmaceuticals Inc disclose cybersecurity risks?
Does Syros Pharmaceuticals Inc offer flexible work?
Does Syros Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Syros Pharmaceuticals Inc disclose the number of employees in R&D functions?
Does Syros Pharmaceuticals Inc conduct supply chain audits?
Does Syros Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Syros Pharmaceuticals Inc conduct 360 degree staff reviews?
Does Syros Pharmaceuticals Inc disclose the individual responsible for D&I?
Does Syros Pharmaceuticals Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Syros Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Does Syros Pharmaceuticals Inc disclose water use targets?
Does Syros Pharmaceuticals Inc have careers partnerships with academic institutions?
Did Syros Pharmaceuticals Inc have a product recall in the last two years?
Does Syros Pharmaceuticals Inc disclose incidents of discrimination?
Does Syros Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Has Syros Pharmaceuticals Inc issued a profit warning in the past 24 months?
Does Syros Pharmaceuticals Inc disclose parental leave metrics?
Does Syros Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Does Syros Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Syros Pharmaceuticals Inc disclose the pay ratio of women to men?
Does Syros Pharmaceuticals Inc support suppliers with sustainability related research and development?
Does Syros Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Syros Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Syros Pharmaceuticals Inc involved in embryonic stem cell research?
Does Syros Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Does Syros Pharmaceuticals Inc disclose its waste policy?
Does Syros Pharmaceuticals Inc report according to TCFD requirements?
Does Syros Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Syros Pharmaceuticals Inc disclose energy use targets?
Does Syros Pharmaceuticals Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Syros Pharmaceuticals Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Syros Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.